IL6 and Miyoshi myopathy: IL-6 influences the pathogenesis of the bone disease of MM through different pathways, such as the expression of RANKL by mesenchymal stem cells (MSCs), the production of proteins involved in bone resorption, inhibition of the anti-osteoclast activity of estrogens, and reduction of bone formation (Ara and Declerck, 2010[5]).